 |
|
|
| |
Multiscale modeling of results from a phase 2 study of an 8-week combination regimen of Bemnifosbuvir and Ruzasvir in patients with chronic hepatitis C virus infection
|
| |
| |
AASLD 2025 Nov 7-11 Wash DC
Carolin Zitzmann1, Ruy M. Ribeiro1, Sergey Izmailyan2, Shannan Lynch2, Keith Pietropaolo2, Arantxa Horga2, Xiao-Jian Zhou2, Janet Hammond2, Alan S. Perelson1 1Theoretical Biology and Biophysics, Los Alamos National Laboratory, NM, United States 2Atea Pharmaceuticals, Inc., Boston, MA, United States
|
| |
|
|
|
|
|
